Dai­ichi Sankyo sinks $200M in­to new gene ther­a­py tech from Ul­tragenyx

In a leap to the gene ther­a­py space, Dai­ichi Sankyo has dropped $200 mil­lion to ac­cess Ul­tragenyx’s man­u­fac­tur­ing tech­nol­o­gy, pro­vid­ing the rare dis­ease biotech with plen­ty of cash and a stock boost amid a gen­er­al cash crunch.

For $125 mil­lion in cash and a $75 mil­lion eq­ui­ty in­vest­ment, Dai­ichi Sankyo has bought a non-ex­clu­sive li­cense to the IP around two plat­forms with which it plans to de­vel­op AAV-based gene ther­a­py prod­ucts. The Japan­ese phar­ma is pur­chas­ing the stock $RARE at $60 per share, more than a third above its cur­rent price of $44.43.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.